Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently...

TUESDAY, July 1, 2025 — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results...

TUESDAY, July 1, 2025 — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results...

FY25 production at Northern Star Resources’ Kalgoorlie operations, which include the Super Pit, has failed to reach revised guidance — although...

FY25 production at Northern Star Resources’ Kalgoorlie operations, which include the Super Pit, has failed to reach revised guidance — although...